Researchers Report Promising Results from Four Clinical Trials Targeting DNA Damage Response and KRAS at AACR Annual Meeting

Patients with recurrent endometrial cancers currently have no good alternatives if first-line therapy fails, but triple therapy with olaparib, cyclophosphamide, and metformin may help. The combination showed good results in heavily pre-treated patients in the ENDOLA trial, an open-label phase I/II trial of the triple combination, according to Benoit You, MD, PhD, Hospices Civils de Lyon, Lyon, France. Dr. You was one of three researchers who presented results of four recent clinical trials on Sunday, April 10, during the plenary session Clinical Trials Targeting the DNA Damage Response and KRAS. This session was part of the AACR 2022 Annual Meeting, April 8-13 in New Orleans. The annual meeting sessions can be viewed on the virtual platform by registered meeting participants through July 13, 2022. Registration can be done here. Over 19,000 scientists and physicians registered for this premier cancer conference, with ~80% (~15,200) attending in person and ~20% (~3,800) attending virtually. The AACR has over 50,000 members worldwide.

Login Or Register To Read Full Story